Press Releases

If you want to subscribe to our press releases please go to the Cision site where it is possible to subscribe.

Note: After January 21, 2020, all press releases are published in English as original language.

ExpreS2ion publishes video from company presentation at a Danish investor event

ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that a filmed company presentation by CEO Bent U. Frandsen at a Danish investor event on October 21, 2020 has been published on the company’s website.

Read more

ExpreS2ion’s rights issue oversubscribed

This is a regulatory release

THIS PRESS RELEASE IS NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION…

Read more

Last day for subscription in the ongoing rights issue is October 19, 2020

This is a regulatory release

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Hørsholm,…

Read more

ExpreS2ion publishes prospectus in connection with capital raise of up to SEK 216 million

This is a regulatory release

THIS PRESS RELEASE IS NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION…

Read more

ExpreS2ion launches a new company website with increased focus on pipeline project development

Hørsholm, Denmark, September 29, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces the launch of a significantly upgraded company website. The new website has a stronger focus on ExpreS2ion’s novel technology platforms and the company’s pipeline project development. It also introduces a separate investor site for improved communication with shareholders, potential investors and other…

Read more

ExpreS2ion and Attana have signed a Development and Supply Agreement

This is a regulatory release

Hørsholm, Denmark, September 24, 2020 – ExpreS2ion Biotech Holding AB hereby announces that its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") and the biotech tools company Attana AB (“Attana”) have today signed a heads of terms agreement regarding the development and supply of novel ExpreS2ion proteins to Attana. The first target protein will be the ExpreS2ion-produced SARS-CoV-2…

Read more

Announcement from the extra general meeting in ExpreS2ion Biotech Holding

This is a regulatory release

The extra general meeting in ExpreS2ion Biotech Holding AB ("ExpreS2ion" or the "Company") was held today on 23 September 2020 and the following resolutions were passed by the meeting.

Read more

ExpreS2ion will present its technology platform and pipeline at several key events in September and October 2020

ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate at several key events in September and October, including Aktiespararna’s Aktiedagen, September 15 in Lund, Sweden, World Vaccine Congress Washington Virtual, September 28–October 1, and World Vaccine Congress Europe Digital Event, October 19–21.

Read more

Analysguiden raises its target price for ExpreS2ion to 24 SEK per share

Hørsholm, Denmark, September 3, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that Aktiespararnars’ Analysguiden has published an updated equity research report on ExpreS2ion. The updated sum-of-the-parts valuation base case is raised to 24 SEK per share after the completion of the proposed rights issue in October 2020 at 12 SEK per share.

Read more

ExpreS2ion announces up to SEK 216 million capital raise through a fully guaranteed rights issue to finance ground breaking vaccine and immunotherapy pipeline

This is a regulatory release

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. INSIDE…

Read more

ExpreS2ion provides update on its expectations to the COVID-19 vaccine program prior to the Q2 2020 report

This is a regulatory release

Hørsholm, Denmark, August 19, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion” or the “Company”) hereby updates the market on its expectations to the development timelines of the COVID-19 vaccine prior to the release of the Company’s Q2 2002 report. The Company now expects the phase III trials to commence as soon as the first half…

Read more

ExpreS2ion appoints new CFO

Hørsholm, Denmark, August 18, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion” or the “Company”) hereby announces that it has appointed Mr. Keith Alexander as new Chief Financial Officer (CFO). Mr. Alexander brings more than 20 years of corporate banking and strategy consulting experience and will initially be focused on strengthening the Company’s financial strategies and…

Read more

ExpreS2ion provides update on anticipated development of the breast cancer vaccine candidate AV001, including a probable change in its ownership stake in AdaptVac

This is a regulatory release

Hørsholm, Denmark, August 18, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion” or the “Company”) hereby announces that ExpreS2ion wishes to exercise the option to inlicense AV001 before it expires on February 26, 2021. The exercise of the option is subject to the Company obtaining the necessary financing to fund the exercise of the option and…

Read more

ExpreS2ion announces exercise of 2017 warrant program

Hørsholm, Denmark, August 3, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion” or “the Company”) today announces that all warrants held by employees and Board members under the 2017 Warrant Program, established in April 2017, have been fully exercised. In total, 436,200 warrants were exercised, providing ExpreS2ion SEK 2,656,632. The exercise has increased the number of shares…

Read more

ExpreS2ion’s joint venture AdaptVac signs Final License Agreement with Bavarian Nordic on COVID-19 Vaccine

This is a regulatory release

Hørsholm, Denmark, July 22, 2020 – ExpreS[2]ion Biotech Holding AB (“ExpreS[2]ion”) hereby announces that its joint venture AdaptVac has entered into a final license agreement with Bavarian Nordic A/S (“Bavarian Nordic”), to license the proprietary capsid virus like particle (cVLP) based SARS-CoV-2 subunit vaccine. Under the terms of the agreement, Bavarian Nordic will make an…

Read more

Strong Proof-of-Concept for cross-strain protective flu cVLP vaccine further strengthens confidence in Coronavirus vaccine

Hørsholm, Denmark, July 17, 2020 – ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) announces that AdaptVac has announced publication of a paper in the journal Vaccines, where its broadly protective Flu cVLP vaccine induced a more potent, long-lasting immune response and was able to protect mice against both homologous and heterologous H1N1 influenza challenge, even after a single…

Read more

ExpreS2ion’s platform to be used in a novel Zika vaccine candidate

Hørsholm, Denmark, July 14, 2020 – ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) announces that its ExpreS2[ ]platform will be used in the production of the novel Zika-HX vaccine candidate that is being developed by Excivion Ltd., a UK-based biotechnology company. The manufacturing of the Zika-HX vaccine will be conducted together with CPI, a British independent technology innovation…

Read more

ExpreS2ion provides update on negotiations with Bavarian Nordic and progress towards clinical Phase I/IIa trial

This is a regulatory release

Hørsholm, Denmark, July 08, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that the cVLP COVID-19 vaccine license agreement negotiation between its joint venture AdaptVac and Bavarian Nordic is expected to continue beyond the previously announced two months’ time frame. The timeline of the already fully funded Phase I/IIa trial is not affected. Process…

Read more

ExpreS2ion announces that the cVLP COVID-19 vaccine shows strong virus neutralization properties in animal proof-of-concept data

This is a regulatory release

Hørsholm, Denmark, June 09, 2020 – ExpreS[2]ion Biotech Holding AB (“ExpreS2ion”) hereby announces that the capsid virus-like particle (cVLP) COVID-19 vaccine being developed by ExpreS2ion and its joint venture AdaptVac has demonstrated excellent COVID-19 immunization with very high level of SARS-CoV-2 virus neutralization in a mice model, thus reaching an important pre-clinical milestone ahead of…

Read more

Communique from the Annual General Meeting in ExpreS2ion Biotech Holding AB (publ)

This is a regulatory release

Today, on May 26[th], 2020, the Annual General Meeting (“AGM”) was held in ExpreS2ion Biotech Holding AB (“ExpreS2ion”). Below follows a summary of the resolutions. The resolutions were passed with the required majority.

Read more

ExpreS2ion Announces Bavarian Nordic Enters Agreement with AdaptVac to Advance the COVID-19 Vaccine Program

This is a regulatory release

Hørsholm, Denmark, May 06, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that its joint venture AdaptVac has entered into an exclusive head of terms agreement with Bavarian Nordic, a global leader in the development, manufacture and commercialization of life-saving vaccines, to license the COVID-19 vaccine. The parties seek to enter into the final…

Read more

ExpreS2ion announces last part of loan conversion and new loan facility

This is a regulatory release

Hørsholm, Denmark, May 04, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that SEK 1.75 million (excluding accrued interest) of the loan provided by Modelio Equity AB (https://news.cision.com/expres2ion-biotechnologies/r/expres-2-ion-secures-sek-8-million-in-bridge-financing-to-facilitate-further-growth,c2933530) (“Modelio”) will be converted into new shares at a price of approximately SEK 9.06 (corresponding to a 10% discount off the last 15 trading days volume-weighted average…

Read more

ExpreS2ion announces supporting an advantageous COVID-19 diagnostic antibody development project

Hørsholm, Denmark, May 4, 2020 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces that its SARS-CoV-2 antigen is being applied across multiple research and development projects, including an on-going diagnostic antibody test program that Rigshospitalet, University of Copenhagen and Novo Nordisk jointly develop to support the diagnosis…

Read more

ExpreS2ion announces selection of AGC Biologics as manufacturing partner for the COVID-19 vaccine and provides update to the program

This is a regulatory release

Hørsholm, Denmark, April 24, 2020 – Today, ExpreS[2]ion Biotechnologies ApS (“ExpreS[2]ion”), a fully owned subsidiary of ExpreS[2]ion Biotech Holding AB, announces that its joint venture AdaptVac and AGC Biologics, a global Contract Development and Manufacturing Organization (CDMO) for Biopharmaceuticals enters into a partnership for the scale-up and cGMP manufacture of the COVID-19 vaccine developed by…

Read more

Notice to Annual General Meeting in ExpreS2ion Biotech Holding AB (publ)

This is a regulatory release

The shareholders of ExpreS2ion Biotech Holding AB (publ), 559033-3729, are hereby invited to attend the Annual General Meeting on Tuesday, May 26, 2020, at 4:00 p.m. at Clarion Grand Hotel, Stortorget 8, in Helsingborg.

Read more

ExpreS2ion announces loan conversion

This is a regulatory release

Hørsholm, Denmark, April 21, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that SEK 1.75 million (excluding accrued interest) of the loan provided by Modelio Equity AB (https://news.cision.com/expres2ion-biotechnologies/r/expres-2-ion-secures-sek-8-million-in-bridge-financing-to-facilitate-further-growth,c2933530) will be converted into new shares at a price of SEK 6.4925 (corresponding to the last 15 trading days volume-weighted average share price).

Read more

ExpreS2ion’s CSO Dr. Wian de Jongh co-signs WHO-sanctioned statement from 83 COVID-19 vaccine researchers

Hørsholm, Denmark, April 15, 2020 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces that the company’s Chief Scientific Officer Dr. Wian de Jongh is a co-signer of a WHO statement from 83 COVID-19 vaccine researchers from all over the world. The statement encourages everyone to follow recommendations…

Read more

ExpreS2ion announces 6.7 MSEK EU Horizon 2020 grant for the development of a unique influenza vaccine

This is a regulatory release

Hørsholm, Denmark, March 31, 2020 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces that the international next-generation influenza vaccine consortium INDIGO, led by the University of Amsterdam with ExpreS2ion as a participating member, has been awarded a 10.0 MEUR Horizon 2020 grant from the EU. ExpreS2ion’s participation…

Read more

ExpreS2ion rearranges its event schedule due to Coronavirus restrictions

ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") is rearranging its recently communicated event schedule due to events changes as a results of COVID-19-related travel restrictions. The company’s main priority during this time is to progress rapidly with the ongoing EU Horizon 2020-funded COVID-19 vaccine development project together with the rest of the consortium…

Read more

ExpreS2ion announces EU grant award for the COVID-19 vaccine development programme

This is a regulatory release

Hørsholm, Denmark, March 6, 2020 – Today, ExpreS[2]ion Biotechnologies ApS (“ExpreS[2]ion”), a fully owned subsidiary of ExpreS[2]ion Biotech Holding AB, announces that the consortium has been awarded an EU Horizon 2020 grant for the COVID-19 (SARS-CoV-2) Coronavirus vaccine development programme. The award funding amounts to 2,7 MEUR (28MSEK), of which ExpreS[2]ion directly is funded with…

Read more

ExpreS2ion will present its ExpreS2 platform and pipeline at several key events in March and April 2020

ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate at several key events in March and April, including Aktiespararna’s Aktiedagen, March 16 in Stockholm, Sweden, BIO-Europe Spring, March 23-25 in Paris, France, and World Vaccine Congress, April 6-8 in Washington, DC, USA.

Read more

ExpreS2ion will be allocated approximately SEK 9,6 million through the redemption of warrants and at the same time converts part of loan

This is a regulatory release

Hørsholm, Denmark, February 26, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that the company has received written confirmation from warrant holders that these parties will exercise all of their warrants of series TO 3. ExpreS2ion will thereby be allocated approximately SEK 9.6 million before issue costs. In connection with this share issue SEK…

Read more

ExpreS2ions Year-End Report for 2019 will be published today

This is a regulatory release

Hørsholm, Denmark, February 26, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that the company’s Year-End Report for 2019 will be published today, as the report is finalized earlier than planned. Previous date for publication of the report was on Friday, the 28[th] of February, 2020.

Read more

ExpreS2ion Signs Option to License Agreement with AdaptVac Regarding Unique Breast Cancer Vaccine

This is a regulatory release

Hørsholm, Denmark, February 26, 2020 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces that the company has signed an Option to License Agreement (“Agreement”) with AdaptVac ApS (“AdaptVac”) whereby ExpreS2ion may call an option to exclusively license in AV001 (HER2-cVLP), a preclinical-stage novel breast cancer vaccine candidate,…

Read more

ExpreS2ion’s joint venture AdaptVac receives Eurostars grant to further support its HER2 vaccine project AV001

This is a regulatory release

Hørsholm, Denmark, February 25, 2020 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces that a consortium led by the company’s joint venture AdaptVac has been awarded a 0.6 MEUR Eurostars grant, of which AdaptVac directly receives 1.3 MDKK (1.8 MSEK). The grant will support pre-clinical safety and…

Read more

ExpreS2ion to lead European COVID-19 vaccine consortium for rapid clinical development

This is a regulatory release

Hørsholm, Denmark, February 24, 2020 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces that the company will lead a consortium of European expert entities in applying for the EU Horizon 2020 and the Coalition for Epidemic Preparedness Innovations (CEPI) grant calls for COVID-19 (SARS-CoV-2) Coronavirus vaccine development.…

Read more

ExpreS2ion announces initiation of a Wuhan Coronavirus vaccine program

This is a regulatory release

Hørsholm, Denmark, February 6, 2020 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces the initiation of a Wuhan Coronavirus (2019-nCoV) vaccine program. ExpreS2ion will produce viral antigens needed for diagnostics and vaccine research, focused on internal vaccine development efforts. The program’s first stage has a timeline of…

Read more

ExpreS2ion’s CEO in interview on 2019 and the company’s new way forward with a stronger pipeline focus

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) publishes an interview with newly appointed CEO Bent Frandsen upon shareholder request. The company’s new way forward with Bent at the helm will include a much stronger focus on building a pipeline portfolio with assets developed in the ExpreS2 platform.

Read more

ExpreS2ion is streamlining its market communication with English as primary language

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that the company has chosen to streamline its market communication, and will only provide press releases and interim reports in English. ExpreS2ion’s annual report will continue to be published in both Swedish and English. 

Read more

ExpreS2ion’s joint venture AdaptVac granted US patent for its core platform technology

This is a regulatory release

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that its joint venture company AdaptVac ApS (“AdaptVac”) has been granted a US patent covering its core technology platform. This confirms the overall patentability and proprietary protection of AdaptVac’s entire pipeline and future projects. In particular, this consolidates the position of the AV001 breast cancer vaccine for which a…

Read more

ExpreS2ion appoints Bent U. Frandsen as Chief Executive Officer

This is a regulatory release

ExpreS[2]ion Biotech Holding AB (“ExpreS[2]ion”) today announces that the Company’s Board of Directors has appointed Bent U. Frandsen as the new Chief Executive Officer of ExpreS[2]ion, succeeding Steen Klysner as of today 20 December, 2019. Bent has been with ExpreS[2]ion since March 2016 and has served as the Company’s Chief Business Officer since August 2018.

Read more

ExpreS2ion has been awarded SEK 2.7 million for continued development of two malaria vaccine candidates

This is a regulatory release

ExpreS[2]ion Biotech Holding AB (“ExpreS[2]ion”) announces that the Company has been awarded SEK 2.7 million as part of the Horizon 2020-funded OptiMalVax grant consortium, led by Jenner Institute at the University of Oxford, to establish monoclonal Drosophila S2 cell banks for two new malaria vaccine candidates. One targets blood-stage malaria, potentially in combination with the…

Read more

ExpreS2ion Biotech Holding AB: Publication of interim report for January – September 2019

This is a regulatory release

ExpreS[2]ion Biotech Holding AB (“ExpreS[2]ion”) hereby publishes its interim report for the period January – September 2019. The report is available as an attached document to this press release and on the Company’s website (www.expres2ionbio.com). Below is a summary of the report.

Read more

Breakthrough: ExpreS2ion launches first unique cell line for enhanced efficacy of vaccines and immunotherapy

This is a regulatory release

After several years of research and development, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces the launch of a new tailormade S2 cell line, HighMan-S2™. This is the first member of ExpreS2ion’s new functionally modified S2 product line, GlycoX-S2™, which utilises and expands the advantages of the ExpreS2 platform.

Read more

ExpreS2ion’s joint venture AdaptVac receives Danish InnoBooster grant of 1.2 MSEK for for breast cancer studies in dogs

This is a regulatory release

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces today that its joint venture company AdaptVac ApS (“AdaptVac”) has been awarded an InnoBooster grant by the Danish Innovation Foundation worth 0.8 MDKK (approx. 1.2 MSEK). The grant provides further resources for the development of a safe and effective treatment for dogs diagnosed with DER2+ cancer. In addition to…

Read more

ExpreS 2 ion secures SEK 8 million in bridge financing to facilitate further growth

This is a regulatory release

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that the Company is increasing its working capital by securing a combination of a bridge loan and a loan facility of up to SEK 8 million in total. This will enable ExpreS2ion to further expand its business activities in line with the growth numbers reported for Q1 and Q2…

Read more

New date for publication of interim report 3

This is a regulatory release

Today, ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that the Company will publish its interim report for the period January – September 2019 on November 14th, 2019, instead of the previously scheduled November 21st, 2019. The aim of the advanced publication is to coordinate the release with the Company’s planned participation in a major public investor…

Read more

ExpreS2ion receives 1.6 MSEK order in development program for next-generation malaria vaccine

This is a regulatory release

ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces that it has received a 1.6 MSEK order to perform development work as part of a Wellcome Trust funded malaria vaccine project. The project is led by Jenner Institute at the University of Oxford, and the goal is to create a…

Read more

ExpreS 2 ion Biotech Holding AB: Publication of interim report for January – June 2019

This is a regulatory release

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby publishes its interim report for the period January – June 2019. The report is available as an attached document to this press release and on the Company’s website (www.expres2ionbio.com). Below is a summary of the report.

Read more

ExpreS2ion’s licensee Institut Virion\Serion launches the first in vitro diagnostic product based on the ExpreS2-platform

This is a regulatory release

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces the Company’s entry on the market for in vitro diagnostic (IVD) applications through its Germany-based licensee Institut Virion\Serion GmbH (“Virion”). Virion is now launching a unique Zika NS1 viral antigen produced in the ExpreS2 platform, and over the next 18 months Virion will increase its offering of products using…

Read more

ExpreS2ion licenses groundbreaking CRISPR/Cas9 gene editing technology from ERS Genomics

This is a regulatory release

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces the signing of a non-exclusive license agreement with ERS Genomics, providing ExpreS2ion with the right to use and commercialise products, for its own use or together with customers or partners, based on the highly efficient CRISPR/Cas9 gene editing technology. This will enable the Company to offer a whole new…

Read more

Change of Certified Adviser to Svensk Kapitalmarknadsgranskning AB

This is a regulatory release

ExpreS2ion Biotech Holding AB (publ) has entered into an agreement with Svensk Kapitalmarknadsgranskning AB (“SKMG”) regarding Certified Adviser services. SKMG will be appointed as Certified Adviser on the 1st of July 2019. Until the 1st of July 2019, Sedermera Fondkommission will continue to act as Certified Adviser for the Company.

Read more

ExpreS2ion co-author of article demonstrating that human antibodies from RH5 vaccine block binding to blood cells

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that a scientific article, documenting that human antibodies against the RH5 protein can stop the malaria parasite from entering human blood cells, has been published in the highly renowned journal Cell. The article is based on a clinical study conducted by researchers at the University of Oxford together with…

Read more

Report from ExpreS2ion Biotech Holding AB’s (publ) annual general meeting

This is a regulatory release

This is an unofficial translation of a report from the Annual General Meeting in ExpreS2ion Biotech Holding AB, originally drafted in Swedish. In case of any discrepancies between the Swedish original and this translation, the Swedish version shall prevail. Today, on May 23, 2019, the annual general meeting of ExpreS2ion Biotech Holding AB (publ) was…

Read more

ExpreS2ion Biotech Holding AB: Publication of interim financial report for January – March 2019

This is a regulatory release

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby publishes financial report for the period of January – March 2019. The report is available as an attached document to this press release and on the Company’s website (www.expres2ionbio.com). Below is a summary of the report.

Read more

ExpreS2ion Biotech Holding AB: Publication of Annual Report for the fiscal year 2018

This is a regulatory release

The Board of Directors and the Chief Executive Officer of ExpreS2ion Biotech Holding AB hereby publishes the Annual Report for the fiscal year 2018. The Annual Report and the accompanying Auditor’s Report is available on the Company’s website (www.expres2ionbio.com).

Read more

ExpreS2ion announces the publication of a proof of concept in animals for a new potential breakthrough malaria vaccine

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces the publication of a scientific article in Cellular Microbiology providing the first proof of concept in an animal model for a next generation malaria vaccine that is targeting a recently discovered molecular ’key’ that the deadly malaria parasite uses to enter human blood cells.

Read more

Correction: Notice to Annual General Meeting in ExpreS2ion Biotech Holding AB (publ)

This is a regulatory release

This is an unofficial translation of a notice to the Annual General Meeting in ExpreS2ion Biotech Holding AB, originally drafted in Swedish. In case of any discrepancies between the Swedish original and this translation, the Swedish version shall prevail. The shareholders of ExpreS2ion Biotech Holding AB (publ), 559033-3729, are hereby invited to attend the Annual…

Read more

Notice to Annual General Meeting in ExpreS2ion Biotech Holding AB (publ)

This is a regulatory release

This is an unofficial translation of a notice to the Annual General Meeting in ExpreS2ion Biotech Holding AB, originally drafted in Swedish. In case of any discrepancies between the Swedish original and this translation, the Swedish version shall prevail. The shareholders of ExpreS2ion Biotech Holding AB (publ), 559033-3729, are hereby invited to attend the Annual…

Read more

ExpreS2ion Biotechnologies Announces Research License Agreement with Mitsubishi Tanabe Pharma Corporation

ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces that Mitsubishi Tanabe Pharma Corporation, Osaka, Japan, has signed a two-year Research License Agreement granting Mitsubishi Tanabe Pharma Corporation access to use ExpreS2ion’s proprietary protein expression platform, ExpreS2 TM , in their Research and Development (R&D).

Read more

Report from Extraordinary General Meeting in ExpreS2ion Biotech Holding AB (publ)

This is a regulatory release

On the 19th of March 2019, an Extraordinary General Meeting in ExpreS2ion Biotech Holding AB was held. Below is a summary of the decisions that were taken. All decisions were taken with required majority.

Read more

ExpreS2ion will attend and present its ExpreS2 technology platform at several key events in March and April

ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate at several key events in March and April, including ISBiotech, March 4-6, in Norfolk, VA, USA, Sedermeradagen, March 12, In Copenhagen, Denmark, and World Vaccine Congress, April 15-17, in Washington, DC, USA. 

Read more

Notice to Extraordinary General Meeting in ExpreS2ion Biotech Holding AB (publ)

This is a regulatory release

The shareholders of ExpreS2ion Biotech Holding AB, 559033-3729, are hereby invited to attend an Extraordinary General Meeting on Tuesday, March 19, 2019, at 10.00 at c/o Mazars SET, Terminalgatan 1, in Helsingborg.

Read more

ExpreS2ion conducts a directed share issue to accelerate the development of the company

This is a regulatory release

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces that the Company is conducting a directed share issue to a number of existing shareholders and strategic investors of initially approx. SEK 8 million, with attached consideration-free warrants, which in later stages can provide the Company with a further approx. SEK 9.6 million. The directed share issue is…

Read more

ExpreS2ion’s joint venture AdaptVac receives SEK 3.6 million grant for vaccine to reduce antibiotic usage in pigs

This is a regulatory release

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that its joint venture AdaptVac ApS (“AdaptVac”) has been awarded approx. SEK 3.6 million by the Danish Innovation Foundation for its participation in a vaccine project aimed at preventing post-weaning diarrhea (PWD), a major cause of antibiotic use in the swine industry.

Read more

ExpreS2ion co-publishes positive phase I placental malaria vaccine results from the PlacMalVac consortium

This is a regulatory release

ExpreS2ion Biotech Holding AB and its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announce that the placental malaria vaccine (PlacMalVac) consortium, of which ExpreS2ion is part, has announced successful phase I clinical study results. The PAMVAC vaccine, manufactured using the ExpreS2 platform, was demonstrated to be safe, well-tolerated and to elicit specific antibody responses in all participants.

Read more

ExpreS2ion’s joint venture AdaptVac receives grants for two new projects: cardiovascular disease and breast cancer in dogs

This is a regulatory release

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that its joint venture AdaptVac ApS (“AdaptVac”) has received DKK 2.2 million (SEK 3.2 million) in funding from the Danish Innovation Foundation for two new vaccine development projects: cardiovascular disease (CVD) in humans and HER2+ breast cancer in dogs. The HER2+ dog project will also be used as preclinical…

Read more

ExpreS2ion’s patent and research partner publishes malaria vaccine breakthrough in Nature

This is a regulatory release

ExpreS2ion Biotech Holding AB (“ExpreS2ion") announces the publication of the first visual image of the molecular ’key’ the deadliest malaria parasite uses to enter human blood cells in Nature. The publication was authored by an international team, including scientists from ExpreS2ion, led by the Walter and Eliza Hall Institute of Medical Research (“WEHI”). This breakthrough…

Read more

ExpreS2ion announces positive Phase I/IIa malaria vaccine trial results by The Jenner Institute, University of Oxford

This is a regulatory release

Horsholm, Denmark, October 31 2018 – Today, ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that The Jenner Institute of the University of Oxford presents positive results from its Phase I/IIa clinical studies with their RH5.1 blood-stage malaria vaccine at a scientific meeting in New Orleans. The vaccine, developed and manufactured using ExpreS2ion’s ExpreS2 platform, was shown…

Read more

ExpreS2ion will present its ExpreS2 technology platform at several key events in October and November

ExpreS2ion Biotech Holding AB and its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announce that the Company will participate at several key events in October and November, including World Vaccine Congress, October 29-31, 2018, in Lisbon, Portugal, and Sedermeradagen, November 7, 2018, in Stockholm, Sweden. 

Read more

ExpreS2ion announces upcoming presentation of Phase I/IIa malaria vaccine trial results by Jenner Institute

This is a regulatory release

Horsholm, Denmark, October 18, 2016 – Today, ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that its collaboration partner, Jenner Institute of the University of Oxford, will present the results from the Phase I/IIa clinical studies of its RH5.1 blood stage malaria vaccine at the annual American Society of Tropical Medicine and Hygiene (ASTMH) meeting on the 31st…

Read more

ExpreS2ion’s proprietary platform used for successful production of another transmission blocking malaria vaccine candidate

ExpreS2ion Biotech Holding AB and its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announce that a recently published scientific article in Nature Communications on the Pfs48/45 malaria vaccine candidate adds further evidence to support that the ExpreS2 platform is an excellent tool for producing transmission blocking malaria vaccines. This is a promising class of next generation vaccines,…

Read more

ExpreS2ion’s joint venture, AdaptVac, receives notice of allowance in the U.S. for its breast cancer vaccine patent

This is a regulatory release

ExpreS2ion Biotech Holding AB and its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announce that its joint venture AdaptVac has received a notice of allowance in the USA for its patent application covering its novel vaccine treatment for HER2-positive breast cancer. This means that the patent is expected to be issued shortly, which is an important step…

Read more

ExpreS2ion’s own Zika virus antigen products included in agreement with U.S.-based Integrated BioTherapeutics

This is a regulatory release

ExpreS2ion Biotech Holding AB’s fully owned subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) announces that it has amended its Research & Commercial License Agreement with U.S.-based partner and licensee Integrated BioTherapeutics (“IBT”) to include own ExpreS2-based products, initially a number of Zika virus antigens.

Read more

ExpreS2ion’s platform (ExpreS2) featured in npj Vaccines article on malaria vaccine candidate production

ExpreS2ion Biotech Holding AB and its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announce that a scientific article on the production of a malaria vaccine candidate using the Company’s ExpreS2 platform was published today in the journal npj Vaccines, a part of Nature Partner Journals Series. The article “Production, quality control, stability, and potency of cGMP-produced Plasmodium…

Read more

ExpreS2ion appoints CBO and IR partner

ExpreS2ion Biotechnologies ApS (“ExpreS2ion") has appointed Bent U. Frandsen, currently VP of Business Development, as Chief Business Officer (CBO). He will manage a proactive effort to substantially increase the customer base in the Company’s vaccine development and production services segment. Furthermore, ExpreS2ion appoints Honeybadger as non-exclusive IR partner on the Swedish market.

Read more

ExpreS2ion will present its malaria and breast cancer vaccine research at two scientific events in June

ExpreS2ion Biotech Holding AB and its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announce that the Company will hold presentations at an annual meeting hosted by the World Biopharm Forum in Oxford, UK, June 20-22 and at the Vaccine Technology VII Meeting in Mont Tremblant, Quebec, Canada, June 17-22.

Read more

ExpreS2ion and GenIbet sign collaboration agreement for vaccine development and GMP production

This is a regulatory release

ExpreS2ion Biotech Holding AB’s fully owned subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) has signed a collaboration agreement regarding vaccine development and GMP (Good Manufacturing Practice) manufacturing with its Portuguese partner GenIbet Biopharmaceuticals, S.A. (“GenIbet”). The agreement strengthens ExpreS2ion’s position as a full-service provider from discovery up to early clinical development.

Read more

Report from ExpreS2ion Biotech Holding AB’s (publ) annual general meeting

This is a regulatory release

Today, May 24th, 2018, the annual general meeting of ExpreS2ion Biotech Holding AB (publ) was held. A summary of the decisions that were made follows below. All decisions were taken with required majority.

Read more

ExpreS2ion’s core platform patent allowed in Canada

This is a regulatory release

ExpreS2ion Biotech Holding AB and its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announce that the Company’s patent application “Improved Protein Expression System”, that covers the entire ExpreS2 platform, has been allowed in Canada and will be granted with expiry June 12, 2029.

Read more

ExpreS2ion Biotech Holding AB: Publication of Annual Report for the fiscal year 2017

This is a regulatory release

The Board of Directors and the Chief Executive Officer of ExpreS2ion Biotech Holding AB hereby publishes the Annual Report for the fiscal year 2017. The Annual Report and the accompanying Auditor’s Report is available on the Company’s website (www.expres2ionbio.com).

Read more

ExpreS2ion’s U.S. partner Integrated BioTherapeutics launches first ExpreS2-based research product

This is a regulatory release

ExpreS2ion Biotech Holding AB’s fully owned subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) announces that its U.S.-based partner and licensee Integrated BioTherapeutics (“IBT”) has initiated sales and marketing of its first ExpreS2-based product. The product, an Ebola virus glycoprotein, is marketed as a part of IBT’s high-quality research protein portfolio and can be used in the development…

Read more

ExpreS2ion Biotech Holding AB:  Last day of trading in BTA

This is a regulatory release

In February 2018, ExpreS2ion Biotech Holding AB (“ExpreS2ion”) conducted a rights issue of shares in which the public also were given the opportunity to subscribe for shares. Through the rights issue, 2,400,403 shares were issued. Last day of trading in BTAs (paid subscription share) is March 15th, 2018 and stop date is March 19th, 2018. 

Read more

ExpreS2ion’s rights issue oversubscribed

This is a regulatory release

Hørsholm, Denmark, March 2nd, 2018 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces that the Company’s rights issue of approximately SEK 19.2 million in order to finance investments in several parts of the core business and also to supply additional working capital for future investments in new business opportunities for both ExpreS2ion and AdaptVac, has…

Read more

ExpreS2ion Biotech Holding AB announces start of subscription period in the rights issue

This is a regulatory release

Today, on February 8th, 2018, the subscription period in ExpreS2ion Biotech Holding AB’s (“ExpreS2ion”) rights issue, starts. The rights issue is also open to the public. The subscription period ends on February 27th, 2018. A fully subscribed rights issue provides ExpreS2ion with approximately SEK 19.2 million before issuing costs. Beforehand, the company has agreed on…

Read more

ExpreS2ion publishes memorandum in relation to the preferential rights issue

This is a regulatory release

Hørsholm, Denmark, February 7th, 2018 – ExpreS2ion Biotech Holding AB (”ExpreS2ion”) hereby publishes its memorandum in Swedish and English in relation to the preferential rights issue, for which the subscription period starts on February 8th. 2018.

Read more

ExpreS2ion resolves on a preferential rights issue to accelerate the Company’s development

This is a regulatory release

Hørsholm, Danmark, January 16, 2018 – ExpreS2ion Biotech Holding AB (”ExpreS2ion”) announces that the Board has decided, pursuant to the authorisation granted by an Extraordinary General Meeting, to carry out a preferential rights issue with the aim to accelerate the Company's development. The preferential rights issue comprises a maximum of 2,400,403 shares with a subscription…

Read more

ExpreS2ion’s core platform patent allowed in India

This is a regulatory release

Hørsholm, Denmark, December 28, 2017 – Today, ExpreS2ion Biotech Holding AB and its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announce that the company’s patent application “Improved Protein Expression System”, that covers the entire ExpreS2 platform, has been allowed in India and will be granted with expiry June 12, 2029.

Read more

ExpreS2ion and Intravacc enter collaboration agreement

This is a regulatory release

Hørsholm, Denmark / Bilthoven, the Netherlands, December 11, 2017 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) and Intravacc (the Institute for Translational Vaccinology), announce the signing of a collaboration agreement. This agreement strengthens ExpreS2ion’s ability to service customers and partners across the full value chain of vaccine development and expands the commercial opportunities for both organisations.…

Read more

ExpreS2ion initiates collaboration on in vitro diagnostic products with Institut Virion\Serion GmbH

This is a regulatory release

Hørsholm, Denmark, December 4, 2017 – Today, ExpreS2ion Biotech Holding AB announces that the fully owned subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) has entered a collaboration with the Germany based Institut Virion\Serion GmbH (“Virion”).  Virion is granted access to evaluate a number of new in vitro diagnostic product candidates, as well as commercial rights to promote,…

Read more

Proof of Concept in Animals for AdaptVac’s breast cancer vaccine candidate published in scientific journal

This is a regulatory release

Hørsholm, Denmark, 28 November 2017 – Today, ExpreS2ion Biotech Holding AB announces that the fully owned subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion”)’s 50% owned joint venture, AdaptVac’s, scientific paper presenting proof of concept in animals (POCA) for its novel breast cancer vaccine candidate, AV001, will be published in the peer reviewed scientific journal ‘OncoImmunology’. The results…

Read more

ExpreS2ion signs commercial license agreement with ABIVAX for using the ExpreS2 platform in their Ebola program

Horsholm, Denmark, April 20, 2017 – Today, ExpreS2ion Biotech Holding AB (“ExpreS2ion”), announces that the fully owned subsidiary ExpreS2ion Biotechnologies […]

ExpreS2ion files joint-patent on the production of an improved malaria vaccine with the Walter and Eliza Hall Institute of Medical Research

Horsholm, Denmark, April 6, 2017 – Today, ExpreS2ion Biotech Holding AB (“ExpreS2ion”), announces that the fully owned subsidiary ExpreS2ion Biotechnologies […]

ExpreS2ion Biotech Holding AB announces that the OptiFemVac Consortium has received final Eurostars approval of its grant application for development of a novel Zika vaccine

Hørsholm, Denmark, March 30, 2017 – Today, ExpreS2ion Biotech Holding AB announces that the fully owned subsidiary ExpreS2ion Biotechnologies ApS […]

ExpreS2ion’s Licensee, VaxInnate, is Winding Down Operations

Horsholm, Denmark, February 9, 2017 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, […]

ExpreS2ion announces the initial approval of a Eurostars grant application, OptiFemVac, with main focus on the development of a Zika vaccine

Horsholm, Denmark, January 23, 2017 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, […]

ExpreS2ion and ABIVAX announce development collaboration on the Ebola prophylaxis and treatment program, ABX544

Horsholm, Denmark and Paris, France, December 12, 2016 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion […]

ExpreS2ion announces the initiation of a Phase I/IIa clinical trial for a new blood-stage malaria vaccine

Horsholm, Denmark, October 18, 2016 – Today, ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that its collaboration partner, the Jenner Institute […]

ExpreS2ion and VaxInnate Sign Research License Agreement

Horsholm, Denmark, September 20, 2016 – Today, ExpreS2ion Biotech Holding AB (“ExpreS2ion”), and VaxInnate Corporation (“VaxInnate”) announce that they have […]

ExpreS2ion Biotech Holding AB: Första dag för handel på Nasdaq Stockholm First North

Idag, den 29 juli 2016, inleds handeln i ExpreS2ion Biotech Holding AB:s (”ExpreS2ion”) aktier på Nasdaq Stockholm First North. Handel […]

ExpreS2ion Biotech announces clinical trial update for the PamVac (Placental Malaria Vaccine) phase I study

ExpreS2ion Biotech announces the second successful evaluation of safety by the independent safety monitoring board for the phase Ia clinical […]

ExpreS2ion Biotech Holding AB approved for listing on Nasdaq Stockholm First North

ExpreS2ion Biotech Holding AB (“ExpreS2ion “) announces that the Company has met the requirements for listing on Nasdaq Stockholm First […]

ExpreS2ion Biotech Holding AB: Listing process delayed

ExpreS2ion Biotech Holding AB herby announces that the listing process at Nasdaq Stockholm First North has been delayed. The company […]

ExpreS2ion Biotech Holding AB’s initial public offering oversubscribed

The 22 June 2016 the subscription period in ExpreS2ion Biotech Holding AB’s (”ExpreS2ion”) initial public offering (”IPO”) of shares at […]

ExpreS2ion Biotech Announces Grant of US Patent

Today, June 21, 2016, ExpreS2ion Biotech Holding AB and its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion Biotech”) announce that its fundamental […]

Today the subscription period of ExpreS2ion Biotech Holding AB’s Initial Public Offering begins

Today, June 8, 2016, the subscription period commences regarding ExpreS2ion Biotech Holding AB’s (“ExpreS2ion”) initial public offering before the planned […]

ExpreS2ion Biotech Holding AB publishes memorandum in advance of the Initial Public Offering

ExpreS2ion Biotech Holding AB (”ExpreS2ion”) hereby publishes the memorandum for the Initial Public Offering which the company plans to commence […]

ExpreS2ion Biotech Holding AB is planning an Initial Public Offering and listing on Nasdaq Stockholm First North

ExpreS2ion Biotech Holding AB (”ExpreS2ion”) hereby announces on May 26th 2016 that the company is planning an Initial Public Offering […]